A First-in-Human,Dose Escalation,Open-Label Study of JAB-3068 in Adult Patients With Advanced Solid Tumors in China

Conditions:   Non-small Cell Lung Cancer;   Head and Neck Cancer;   Esophageal Cancer;   Other Metastatic Solid Tumors
Intervention:   Drug: JAB-3068
Sponsor:   Jacobio Pharmaceuticals Co., Ltd.
Not yet recruiting

https://ift.tt/2tp42XB